Table 1.
Baseline characteristics of the study population
| Characteristics | Control n = 12 |
ID-HTN n = 10 |
P value |
|---|---|---|---|
| Age, yr | 47.0 ± 2.8 | 47.1 ± 4.3 | 0.980 |
| Sex, male/female | 5/7 | 6/4 | 0.392 |
| Race, black/white | 12/0 | 9/1 | 0.262 |
| Weight, kg | 90.5 ± 6.3 | 89.6 ± 8.4 | 0.930 |
| Body mass index, kg/m2 | 30.4 ± 1.7 | 29.2 ± 2.0 | 0.651 |
| Baseline muscle sympathetic nerve activity | |||
| Burst frequency, bursts/min | 36.8 ± 3.9 | 27.1 ± 2.9 | 0.066 |
| Burst incidence, bursts/100 heart beats | 52.2 ± 5.2 | 38.4 ± 5.8 | 0.108 |
| Hemodynamics | |||
| Systolic BP, mm Hg | 130 ± 8 | 141 ± 10 | 0.356 |
| Diastolic BP, mm Hg | 76 ± 3 | 78 ± 5 | 0.813 |
| Heart rate, bpm | 79 ± 3 | 75 ± 4 | 0.813 |
| Diabetes, n (%) | 4 (33) | 1 (10) | 0.193 |
| Hypertension, n (%) | 9 (75) | 10 (100) | 0.089 |
| Etiology of end-stage renal disease, n (%) | |||
| Hypertension | 6 (50) | 9 (90) | 0.045 |
| Diabetes | 2 (17) | 1 (10) | 0.650 |
| Glomerulonephritis | 3 (25) | 0 (0) | 0.089 |
| Unspecified | 1 (8) | 0 (0) | 0.350 |
| Antihypertensive medications, n (%) | |||
| Calcium channel blockers | 3 (25) | 7 (70) | 0.035 |
| ACEIs/ARBs | 4 (33) | 7 (70) | 0.087 |
| β-Blockers | 7 (58) | 7 (70) | 0.571 |
ACEIs, angiotensin-converting enzyme inhibitors; ARBs, angiotensin receptor blockers; BP, blood pressure.
Values with plus-or-minus sign are mean ± SE. Bold indicates statistically significant P values < 0.05.